<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01422707</url>
  </required_header>
  <id_info>
    <org_study_id>CBS003</org_study_id>
    <secondary_id>CBS003</secondary_id>
    <nct_id>NCT01422707</nct_id>
  </id_info>
  <brief_title>Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess</brief_title>
  <official_title>Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS003)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Short term hydrocortisone to test whether improves excess androgen production from adrenal&#xD;
      gland and ovaries&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test whether short-term suppression of adrenal function can ameliorate&#xD;
      androgen (male hormone) overproduction in overweight girls with androgen excess. The&#xD;
      investigators hypothesize that one month of oral hydrocortisone administration will improve&#xD;
      androgen levels in girls with adrenal androgen overproduction. Specifically, this&#xD;
      intervention will improve androgen levels after adrenal stimulation testing with&#xD;
      adrenocorticotropin hormone (ACTH).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study team decided not to pursue this study.&#xD;
  </why_stopped>
  <start_date type="Actual">January 19, 2018</start_date>
  <completion_date type="Actual">July 17, 2018</completion_date>
  <primary_completion_date type="Actual">July 17, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in free testosterone after ACTH administration before and after hydrocortisone administration for 4 weeks</measure>
    <time_frame>30 and 60 minutes after ACTH, baseline, and after 4 weeks of hydrocortisone administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in adrenal steroid precursors after ACTH, baseline, and after 4 weeks of hydrocortisone administration</measure>
    <time_frame>30 and 60 minutes after ACTH, baseline, and after 4 weeks of hydrocortisone administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hyperandrogenemia</condition>
  <condition>Obesity</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks hydrocortisone with pre- and post-intervention Dexamethasone and Cosyntropin to perform standardized adrenal stimulation testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>10 mg/m2/per day PO at bedtime (X4 weeks)</description>
    <arm_group_label>hydrocortisone</arm_group_label>
    <other_name>Cortef</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overweight(&gt;85th BMI%) females&#xD;
&#xD;
          -  Early to late puberty (expected age range 7-18)&#xD;
&#xD;
          -  Hyperandrogenemic (free testosterone greater than 2.5 standard deviations above the&#xD;
             mean for normal control subjects of the same Tanner Stage)&#xD;
&#xD;
          -  Screening labs within age-appropriate normal range, with the exception of a mildly low&#xD;
             hematocrit (see below) and the hormonal abnormalities inherent in obesity which could&#xD;
             include mildly elevated luteinizing hormone (LH), lipids, testosterone, prolactin,&#xD;
             DHEAS, E2, glucose, and insulin; and decreased follicle-stimulating hormone (FSH)&#xD;
             and/or sex hormone-binding globulin (SHBG)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Screening labs outside of age-appropriate normal range&#xD;
&#xD;
          -  Hemoglobin &lt;12 mg/dL and hematocrit&lt;36% (Subjects will be offered the opportunity to&#xD;
             take iron supplementation for 60 days if their hematocrit is slightly low (33-36%)&#xD;
             (suggestive of iron deficiency anemia) and will then return for retesting of their&#xD;
             hemoglobin/hematocrit. If still &lt;36%, they will be excluded.)&#xD;
&#xD;
          -  Morning Cortisol &lt;5 g/dL&#xD;
&#xD;
          -  17-hydroxyprogesterone &gt;295 ng/dL&#xD;
&#xD;
          -  History of Cushing's syndrome or adrenal insufficiency&#xD;
&#xD;
          -  Pregnant&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine M. Burt Solorzano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Center for Research in Reproduction</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>August 19, 2011</study_first_submitted>
  <study_first_submitted_qc>August 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2011</study_first_posted>
  <last_update_submitted>July 17, 2018</last_update_submitted>
  <last_update_submitted_qc>July 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Christine Burt Solorzano</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Hyperandrogenism</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

